SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (7383)2/28/2004 2:56:42 PM
From: Biomaven  Read Replies (1) of 10280
 
I can't argue that the company will be a very attractive acquisition target in a year or so. What always amazed me that there wasn't any pharma (or even large biotech) that was willing to look past their next several quarters earnings reports and snaffle up SEPR when the stock was in the low single digits.

If Sanofi fails at munching Aventis, then SEPR might be another entree for it into the US market, albeit on a smaller scale. (The same is true for the other European pharma - e.g, Merck KG). Aside from the pharma, SEPR and FRX will be the only companies with a general (non-niche) US sales force.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News